Recruiting studies: Advanced Thyroid Gland Medullary Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT07016230 Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Phase 4 · 19 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT05830500 Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
NA · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06141369 Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
Phase N/A · 2 location(s) · M.D. Anderson Cancer Center · NCT04216732

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.